Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503051 | 0.86 | MEN1 (0.40) | LMNASMN1; SMN2HTTPARP1AKR1B1 | |
| SCHEMBL4502923 | 0.85 | AKR1B1 (0.41) | LMNASMN1; SMN2HTTPARP1AKR1B1 | |
| SCHEMBL4482008 | 0.85 | AKR1B1 (0.42) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4484750 | 0.84 | AKR1B1 (0.40) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4488507 | 0.81 | AKR1B1 (0.47) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4494967 | 0.79 | POLB (0.46) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4484069 | 0.79 | MEN1 (0.48) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4492134 | 0.77 | TP53 (0.46) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL6031141 | 0.76 | LMNA (0.47) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 | |
| SCHEMBL4481403 | 0.75 | PRKAA2 (0.41) | LMNASMN1; SMN2HTTAKR1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | LMNA 4273/4885SMN1; SMN2 4492/4885HTT 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.